Loading
An Indian company with a Singapore affiliate that develops OncoVeryx, a serum metabolomics blood test it reports can detect 30 cancers.
PredOmix Technologies Private Limited, Gurugram, and PredOmix Health Sciences, Singapore, according to their authors' affiliations, combine untargeted serum metabolomics with machine learning. Its employees have published versions of the test for four, fifteen and thirty cancers, the last in an investigator-initiated trial with HCG cancer centres (CTRI/2023/03/050316).
An Indian blood test that reads thousands of small molecules in serum; its developer reports about 98% accuracy for 30 cancers, figures that have not been checked independently.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/